DM Research, Inc. v. College of American Pathologists

170 F.3d 53, 1999 WL 104446
CourtCourt of Appeals for the First Circuit
DecidedMarch 7, 1999
Docket98-1555
StatusPublished
Cited by169 cases

This text of 170 F.3d 53 (DM Research, Inc. v. College of American Pathologists) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DM Research, Inc. v. College of American Pathologists, 170 F.3d 53, 1999 WL 104446 (1st Cir. 1999).

Opinion

BOUDIN, Circuit Judge.

DM Research, Inc., the plaintiff in the district court, is a Rhode Island company that for many years has been engaged in the production of reagents, which are substances used in the testing or synthesis of other products. The defendants in the district court were two organizations: the College of American Pathologists (“the College”), a nonprofit Illinois corporation comprising several hundred pathologists, and the National Committee for Clinical Laboratory Standards (“National”), a nonprofit Pennsylvania corporation representing a variety of manufacturing, testing, and other interests.

Since the case was resolved below on a motion to dismiss, we take the factual allegations of the complaint as true. See Watter-son v. Page, 987 F.2d 1, 3 (1st Cir.1993). Among other products DM Research makes is what its complaint calls “reagent grade water,” a form of purified water used in clinical laboratories for various purposes. National’s main role is to develop uniform standards relating to clinical laboratory testing; its standards, like those of most private standard-setting organizations, have no legal force but may be followed voluntarily or used in certification arrangements.

In 1991, National adopted a guideline document titled “Preparation and Testing of Reagent Water in the Clinical Laboratory, Approved Guideline” (2d ed. Aug.1991). The guidelines set down minimum requirements reagent water should meet, e.g., as to bacterial content, pH, resistance to electrical transmission, silicate content, particulate content, and organic content. According to the complaint, one of the guidelines effectively requires complying laboratories — at least for certain procedures — to use reagent water produced using a purification system on site, rather than using bottled reagent water manufactured elsewhere. National’s guidelines require just-produced water for certain laboratory tests on the ground that the resistivity of the water tends to degrade rapidly over time.

Equipment, apparently costing $1,000 or more, is available for on-site production of reagent water. Laboratories that choose to comply with the National guideline at issue now purchase such equipment instead of buying reagent water from DM Research or its competitors. In DM Research’s view, National’s requirement of on-site production is scientifically unjustified. The details of this scientific quarrel are not important for present purposes; we assume arguendo that DM Research could prove at trial that National’s guideline is unnecessary.

Although the National reagent water guidelines have no legal force, the College has incorporated them into its own guidelines, which it uses in accrediting laboratories, including hospital laboratories. According to the DM Research complaint, the loss of such accreditation would, as a practical matter, be “devastating” to a laboratory. And while the complaint is quite obscure on this point, we will assume that DM Research could prove at trial that many of DM Research’s potential, customers have strong practical reasons for complying with the College’s guidelines even though they may have no legal obligation to do so.

*55 The complaint alleges that the effect of the National guidelines and their adoption by the College was to limit the growth in DM Research’s sales of its reagent water and ultimately to force the owner of DM Research to sell the company at reduced price. The complaint charged, inter alia, that National and the College had conspired to restrain trade in the provision of high grade reagent water products, including bottled reagent water and water purification equipment, thereby violating section 1 of the Sherman Act, 15 U.S.C. § 1.

The complaint says that the provision of such products to laboratories constitutes a national “market,” within the meaning of the antitrust laws, and solely for purposes of our decision we will assume this to be so. It also says that the acts in furtherance of the conspiracy were as follows:

(a) the creation, adoption, and enforcement of faulty and arbitrary standards and guidelines and (b) economic threats and intimidation of certain laboratories and referring pathologists to cease or refrain from doing business with DM Research and other bottled reagent water manufacturers.

What weight is to be given to allegations of this character, and to the general charge of “conspiracy,” is the central issue in this case.

The College moved to dismiss, Fed. R.Civ.P. 12(b)(6), on the ground that the complaint failed to state a claim under the Sherman Act; National moved to dismiss for this reason and for lack of personal jurisdiction and venue. DM filed an opposition but no affidavits. In a thoughtful memorandum and order, dated April 14, 1998, the district judge granted the motion to dismiss the Sherman Act count for failure to state a claim and, declining to exercise supplemental jurisdiction, see 28 U.S.C. § 1367, dismissed without prejudice the remaining state law claims (state antitrust, tortious interference, and defamation). See DM Research, Inc. v. College of American Pathologists, 2 F.Supp.2d 226 (D.R.I.1998).

On DM Research’s appeal, our review of the district court’s decision is de novo. See Preferred Mutual Ins. Co. v. Travelers Cos., 127 F.3d 136, 137 (1st Cir.1997). The issue is whether the complaint states a claim under the Sherman Act, assuming the factual allegations to be true and indulging to a reasonable degree a plaintiff who has not yet had an opportunity to conduct discovery. See Watterson, 987 F.2d at 3. The issue turns as much on a recurring problem of civil procedure—what force is to be accorded con-clusory terms in a complaint—as it does on antitrust analysis.

The governing precept, to borrow the district court’s excellent summary, is that while the plaintiffs “facts” must be accepted as alleged, this does not automatically extend to “[b]ald assertions, subjective characterizations and legal conclusions,” 2 F.Supp.2d at 228 (citing cases); further, as the district judge said, “the factual allegations must be specific enough to justify ‘drag[ging] a defendant past the pleading threshold,’ ” id. at 228 (quoting Gooley v. Mobil Oil Corp., 851 F.2d 513, 514 (1st Cir.1988)).

Gooley’s concept of “the pleading threshold” is critical. The complaint should include “a short and plain statement” of the claim showing that the pleader is entitled to relief, Fed.R.Civ.P. 8(a), so it need not include evidentiary detail. On the other hand, the price of entry, even to discovery, is for the plaintiff to allege a factual predicate concrete enough to warrant further proceedings, which may be costly and burdensome.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burke v. Deml
Vermont Superior Court, 2024
leblanc v. estate of snelgrove
Vermont Superior Court, 2024
Nowell v. Medtronic Inc.
372 F. Supp. 3d 1166 (D. New Mexico, 2019)
Cindy Laine Franklin v. Chris Curry
738 F.3d 1246 (Eleventh Circuit, 2013)
SouthBARK, Inc. v. Mobile County Commission
974 F. Supp. 2d 1372 (S.D. Alabama, 2013)
Mediostream, Inc. v. Microsoft Corp.
869 F. Supp. 2d 1095 (N.D. California, 2012)
CANMAN v. Bonilla
778 F. Supp. 2d 179 (D. Puerto Rico, 2011)
In Re Iowa Ready-Mix Concrete Antitrust Litigation
768 F. Supp. 2d 961 (N.D. Iowa, 2011)
Process Controls Intern. v. Emeron Process Mgmt.
753 F. Supp. 2d 912 (E.D. Missouri, 2010)
Allen v. Dairy Farmers of America, Inc.
748 F. Supp. 2d 323 (D. Vermont, 2010)
United States Ex Rel. Carpenter v. Abbott Laboratories, Inc.
723 F. Supp. 2d 395 (D. Massachusetts, 2010)
Reisinger v. Luzerne County
712 F. Supp. 2d 332 (M.D. Pennsylvania, 2010)
NEC v. Drew University et al.
D. New Hampshire, 2009
Segelman v. City of Springfield
561 F. Supp. 2d 123 (D. Massachusetts, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
170 F.3d 53, 1999 WL 104446, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dm-research-inc-v-college-of-american-pathologists-ca1-1999.